Gilead Sciences
About
Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company with a dominant franchise in HIV treatment and prevention, generating billions in annual revenue from drugs like Biktarvy and Descovy. The company is also expanding in oncology through its acquisition of Immunomedics and development of cell therapy treatments. GILD's strong free cash flow supports a growing dividend and aggressive share repurchase program, making it a rare combination of biotech innovation and income generation.
Biotech Stocks
Gilead Sciences is a biotech pioneer in antiviral therapies, with groundbreaking treatments for HIV and hepatitis C, and is expanding its oncology pipeline through acquisitions and internal development of cell therapies and antibody-drug conjugates.
Dividend Stocks
Gilead Sciences pays a growing quarterly dividend supported by robust free cash flow, offering investors a rare combination of biotech-level innovation with the income characteristics typically associated with mature pharmaceutical companies.
Pharmaceutical Stocks
Gilead Sciences is a major pharmaceutical company with a dominant franchise in HIV treatment and prevention, generating billions in annual revenue from its market-leading antiretroviral therapies including Biktarvy.
Key Financials GILD
Price
$154.98
Change (1D)
+2.09%
Change (30D)
+26.27%
Change (60D)
+24.89%
Change (90D)
+36.45%
Change (180D)
+42.92%
Change (1Y)
+50.01%
Change (5Y)
+130.28%
P/E Ratio
17.81
EPS (TTM)
$8.70
52-Week Range
$93.37 — $157.29
50-Day MA
$130.17
Volume
6.86M
Data updated Feb 15 · Source: Twelve Data
